Articles tagged with Heterodimers
TOR protein's molecular switch regulator, SEA complex, has been structurally solved by CNIO researcher Lucas Tafur. The study reveals that SEA doesn't regulate TOR in the way previously thought, providing new insights into understanding cancer and disease prevention.
Researchers characterized the structure and function of a protein that regulates sugar and fat levels, finding it can work with an unexpected partner - itself. This partnership may drive the expression of different genes than its usual partner, offering new therapeutic targets for diseases like liver cancer and diabetes.
A novel mechanism for splicing human short introns has been discovered using the SAP30BP-RBM17 complex. The researchers confirmed that the established pre-mRNA splicing mechanism cannot work in a subset of human short introns.
The study found that Ponatinib inhibits Src-mediated ESCC malignancy with no toxic effect on normal cells. Src interacts with Fyn or Lyn to form heterodimers, which play a key role in ESCC development. Overactivation of specific tyrosine residues can be used as biomarkers for ESCC prognosis.
Scientists harness higher-order protein catenation to create complexed proteins with potential as artificial antibodies. The new method enables the synthesis of protein [n]catenanes, which show improved binding affinity and prolonged serum half-life.
PKU researchers harness higher order protein catenation to create complexed topological proteins, leading to the synthesis of artificial antibodies with enhanced affinity and prolonged serum half-life. The study successfully expands toolkits for protein entangling motifs, promoting advanced protein therapeutics.
A team of researchers has identified a novel splicing mechanism for human short introns, involving the distinct factor SPF45. This discovery sheds light on alternative splicing and its potential applications in cancer treatment.
Scientists at the University of Münster have decoded a mechanism that regulates the release of S100A8/S100A9 protein complexes, which can trigger or amplify inflammatory reactions. The researchers aim to develop new treatment options for autoimmune diseases and inflammatory disorders with fewer side effects.
A study by Osaka University reveals that a single heterodimer of two T1r members can detect a wide range of sweet and savory flavors in humans. The researchers found that the structure of the heterodimer is similar regardless of the amino acid bound, but with varying affinity for each ligand.
A systematic analysis of chemokine interactions reveals two structural types with different functional effects on inflammation. The study identifies potential therapeutic targets using specially designed peptides that selectively inhibit atherosclerosis and acute inflammation.
Scientists developed a microfluidics-based technique called SMiLE-seq to characterize DNA-binding proteins, increasing speed, accuracy and efficiency. The technique can analyze over 60 transcription factors, including nine new ones, and has the potential to be extended to other molecules.
Researchers have devised a new method for synthesizing communesins, a group of fungal compounds with anticancer properties, by transforming carbon atoms into radicals and joining them together. This approach enables the production of designed variants with potentially greater potency.
The study reveals the precise structure of the mosquito-transmitted chikungunya virus pathogen bound to antibodies, showing how infection is likely neutralized. Antibodies stabilize the viral surface, hindering fusion and blocking infection. The findings could lead to effective vaccines against the infection.
The Ku heterodimer, a key player in non-homologous end joining (NHEJ), is shown to 'cradle' broken DNA ends with its ring-shaped molecule, forming a precise alignment for repair enzymes. This structure provides insights into the accuracy of the NHEJ process and its importance in genome integrity.